تقرير
أعرض في EDS

Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics.

التفاصيل البيبلوغرافية
العنوان: Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics.
المؤلفون: Meziyerh S; Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.; LUMC Transplant Center, Leiden University Medical Center, Leiden, The Netherlands., Zwart TC; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands., van Etten RW; Department of Internal Medicine, Division of Nephrology, Amphia Hospital, Breda, The Netherlands., Janson JA; Department of Intensive Care, Leiden University Medical Center, Leiden, The Netherlands., van Gelder T; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands., Alwayn IPJ; LUMC Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.; Department of Surgery, Division of Transplantation Surgery, Leiden University Medical Center, Leiden, The Netherlands., de Fijter JW; Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.; LUMC Transplant Center, Leiden University Medical Center, Leiden, The Netherlands., Reinders MEJ; Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.; LUMC Transplant Center, Leiden University Medical Center, Leiden, The Netherlands., Moes DJAR; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands., de Vries APJ; Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.; LUMC Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
المصدر: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2020 Jul; Vol. 20 (7), pp. 1896-1901. Date of Electronic Publication: 2020 May 13.
نوع المنشور: Case Reports
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 100968638 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-6143 (Electronic) Linking ISSN: 16006135 NLM ISO Abbreviation: Am J Transplant Subsets: MEDLINE
أسماء مطبوعة: Publication: 2023- : [New York] : Elsevier
Original Publication: Copenhagen : Munksgaard International Publishers, 2001-
مواضيع طبية MeSH: Kidney Transplantation* , Transplant Recipients*, Coronavirus Infections/*complications , Coronavirus Infections/*therapy , Everolimus/*pharmacokinetics , Kidney Failure, Chronic/*complications , Pneumonia, Viral/*complications , Pneumonia, Viral/*therapy, Adult ; Antiviral Agents/administration & dosage ; Antiviral Agents/pharmacokinetics ; Betacoronavirus ; COVID-19 ; Chloroquine/administration & dosage ; Chloroquine/pharmacokinetics ; Drug Combinations ; Drug Interactions ; Everolimus/administration & dosage ; Humans ; Immunocompromised Host ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/pharmacokinetics ; Kidney Failure, Chronic/surgery ; Lopinavir/administration & dosage ; Lopinavir/pharmacokinetics ; Male ; Netherlands ; Pandemics ; Radiography, Thoracic ; Ritonavir/administration & dosage ; Ritonavir/pharmacokinetics ; SARS-CoV-2 ; Treatment Outcome
مستخلص: The current coronavirus disease 2019 (COVID-19) pandemic requires extra attention for immunocompromised patients, including solid organ transplant recipients. We report on a case of a 35-year-old renal transplant recipient who suffered from a severe COVID-19 pneumonia. The clinical course was complicated by extreme overexposure to the mammalian target of rapamycin inhibitor everolimus, following coadministration of chloroquine and lopinavir/ritonavir therapy. The case is illustrative for dilemmas that transplant professionals may face in the absence of evidence-based COVID-19 therapy and concurrent pressure for exploration of experimental pharmacological treatment options. However, the risk-benefit balance of experimental or off-label therapy may be weighed differently in organ transplant recipients than in otherwise healthy COVID-19 patients, owing to their immunocompromised status and potential drug interactions with immunosuppressive therapy. With this case report, we aimed to achieve increased awareness and improved management of drug-drug interactions associated with the various treatment options for COVID-19 in renal transplant patients.
(© 2020 The Authors. American Journal of Transplantation published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.)
References: Clin Pharmacokinet. 2007;46(1):13-58. (PMID: 17201457)
N Engl J Med. 2020 May 7;382(19):1787-1799. (PMID: 32187464)
Semin Respir Crit Care Med. 2007 Apr;28(2):222-42. (PMID: 17458776)
Int J Infect Dis. 2020 May;94:68-71. (PMID: 32179140)
N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013)
PLoS Med. 2006 Sep;3(9):e343. (PMID: 16968120)
Lancet Infect Dis. 2007 Aug;7(8):549-58. (PMID: 17646028)
Nephron. 1992;62(1):108-9. (PMID: 1436274)
N Engl J Med. 2020 Apr 23;382(17):1653-1659. (PMID: 32227760)
Am J Transplant. 2020 Jul;20(7):1859-1863. (PMID: 32181990)
Kidney Int. 2020 May;97(5):824-828. (PMID: 32204907)
Liver Transpl. 2020 Jun;26(6):832-834. (PMID: 32196933)
J Gen Virol. 2011 Nov;92(Pt 11):2542-2548. (PMID: 21752960)
AIDS Patient Care STDS. 2012 Oct;26(10):568-81. (PMID: 23025916)
BMC Infect Dis. 2016 Apr 21;16:174. (PMID: 27097824)
Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84. (PMID: 24841269)
Nephron. 1993;65(2):333. (PMID: 8247209)
Clin Pharmacokinet. 2012 Nov;51(11):711-41. (PMID: 23018468)
Am J Transplant. 2020 Jul;20(7):1875-1878. (PMID: 32198834)
فهرسة مساهمة: Keywords: clinical decision-making; clinical research/practice; drug interaction; immunosuppressive regimens; infection and infectious agents - viral; infectious disease; kidney transplantation/nephrology; pharmacokinetics/pharmacodynamics; pharmacology
المشرفين على المادة: 0 (Antiviral Agents)
0 (Drug Combinations)
0 (Immunosuppressive Agents)
0 (lopinavir-ritonavir drug combination)
2494G1JF75 (Lopinavir)
886U3H6UFF (Chloroquine)
9HW64Q8G6G (Everolimus)
O3J8G9O825 (Ritonavir)
تواريخ الأحداث: Date Created: 20200428 Date Completed: 20200720 Latest Revision: 20230124
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7267503
DOI: 10.1111/ajt.15943
PMID: 32337790
قاعدة البيانات: MEDLINE
الوصف
تدمد:1600-6143
DOI:10.1111/ajt.15943